Omeros (NASDAQ:OMER) VP Sells $463,500.00 in Stock

Omeros Corporation (NASDAQ:OMER) VP Peter Cancelmo sold 25,000 shares of the firm’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $18.54, for a total value of $463,500.00. Following the sale, the vice president directly owned 200 shares in the company, valued at approximately $3,708. The trade was a 99.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Omeros Price Performance

Shares of NASDAQ:OMER traded down $0.05 during midday trading on Tuesday, hitting $19.39. The company had a trading volume of 387,803 shares, compared to its average volume of 1,687,194. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of 15.15 and a beta of 2.60. The business’s 50-day simple moving average is $16.40 and its 200-day simple moving average is $13.11. Omeros Corporation has a twelve month low of $4.05 and a twelve month high of $21.24.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. As a group, sell-side analysts forecast that Omeros Corporation will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of OMER. Assetmark Inc. bought a new stake in Omeros during the first quarter worth approximately $38,000. International Assets Investment Management LLC grew its holdings in Omeros by 16.0% during the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 800 shares during the period. Leonteq Securities AG acquired a new position in Omeros during the first quarter valued at approximately $106,000. Farther Finance Advisors LLC increased its position in shares of Omeros by 16.5% in the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,004 shares during the period. Finally, Engineers Gate Manager LP acquired a new stake in shares of Omeros during the 2nd quarter valued at $138,000. Institutional investors own 48.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on OMER shares. Cantor Fitzgerald upgraded Omeros from a “neutral” rating to an “overweight” rating and set a $22.00 target price for the company in a research report on Tuesday, September 22nd. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Weiss Ratings downgraded shares of Omeros from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 22nd. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

About Omeros

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.